The Role of Androgen Receptor Inhibitors in the Management of Advanced Prostate Cancer

EP1: Collaborative approaches to treating advanced prostate cancer

October 14th 2021

The role of urologists in working with medical oncologists to treat patients with advanced prostate cancer, with special considerations for early referral.

EP2: AR-targeted therapies for advanced prostate cancer

October 14th 2021

Julie N. Graff, MD, of OHSU Knight Cancer Institute, comments on the impact of the availability of newer-generation androgen receptor inhibitors on treatment outcomes for patients with advanced prostate cancer.

EP3: AR-targeted therapies for mCSPC

October 21st 2021

Various factors that medical oncologists consider when selecting to treat metastatic castration-sensitive prostate cancer with either apalutamide or enzalutamide.

EP4: AR-targeted therapies for nmCRPC

October 21st 2021

Julie N. Graff, MD, highlights the efficacy associated with the use of androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer.

EP5: AR inhibitor treatment selection in nmCRPC

October 28th 2021

Considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.

EP6: Next steps investigating AR inhibitors in advanced prostate cancer

October 28th 2021

Based on long-term data and clinical experience treating advanced prostate cancer with androgen receptor inhibitors, Drs Julie N. Graff and Benjamin H. Lowentritt suggest ideas for future study.

EP7: PSA kinetics in advanced prostate cancer

November 4th 2021

In response to a presentation from AUA 2021, Dr. Julie N. Graff considers the role of PSA kinetics as prognostic markers in advanced prostate cancer.

EP8: Interpreting real-world data in advanced prostate cancer

November 4th 2021

Current limitations of real-world data available that support the use of novel therapies, including androgen receptor inhibitors, as treatment for advanced prostate cancer.

EP9: Novel dual agents for advanced prostate cancer

November 4th 2021

A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.